Monopar Therapeutics Reports Q3 GAAP EPS of -$0.72 in Line with Expectations
Monopar Therapeutics (MNPR) has reported its third-quarter financial results, posting a GAAP earnings per share (EPS) of -$0.72, which aligned with market expectations. As of September 30, 2026, the company held $129.4 million in cash, cash equivalents, and investments. The company maintains a strong liquidity position, projecting that its current capital reserves will support operations through at least March 31, 2028. These funds are earmarked for regulatory and commercial activities related to ALXN1840, the continued development of MNPR-101 programs, and ongoing internal research and development efforts.
Tickers: $MNPR
Topics: biotechnology cash runway earnings report financial results